Risk Factors of Dyspepsia Development during Anti-tuberculosis Chemotherapy in Children
https://doi.org/10.21292/2075-1230-2022-100-9-6-10
Abstract
The objective: to identify factors influencing the development of dyspepsia in children during treatment with anti-tuberculosis drugs.
Results: out of 243 children during chemotherapy, 22.6% developed dyspepsia as an adverse reaction. Risk factors significantly associated with the development of dyspepsia were as follows: formula feeding at birth, comorbidities of the gastrointestinal tract, decreased total protein and elevated leukocyte counts by the admission to hospital, tuberculosis treatment as per regimens IV or V, and inclusion of protionamide or para-aminosalicylic acid to the regimen. Based on the method of logistic regression, the following has been developed: the method to predict the risk of developing dyspepsia during anti-tuberculosis chemotherapy in children with a sensitivity of 93%; the PC software to calculate such a risk.
About the Authors
E. O. Bryukhacheva
Kemerovo State Medical University
Russian Federation
Russian Federation
Ekaterina O. Bryukhacheva, Post Graduate Student of Phthisiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-54-56-51
A. A. Kholodov
Kemerovo State Medical University
Russian Federation
Russian Federation
Artem A. Kholodov, Resident Physician of Phthisiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-54-56-51
V. I. Ivanov
Kemerovo State Medical University
Russian Federation
Russian Federation
Vadim I. Ivanov, Candidate of Biological Sciences, Associate Professor of Human Physiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-73-29-84
G. A. Kazul
I. F. Kopylova Kuzbass Clinical Phthisiopulmonary Medical Center
Russian Federation
Russian Federation
Galina A. Kazul, Head of Pediatric Department
5, Khimikov St., Kemerovo, 650036
Phone: 384-2-64-27-36
T. V. Pyanzova
Kemerovo State Medical University
Russian Federation
Russian Federation
Tatiana V. Pyanzova, Doctor of Medical Sciences, Associate Professor, Head of Phthisiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-54-56-51
References
1. Aksenova V.A., Klevno N.I., Kazakov A.V., Kudlay D.A., Pakhlavonova A.D., Sokolskaya E.A., Nakonechnaya S.L. Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis Meditsinsky Soviet, 2021, no. 16, pp. 138-146. (In Russ.)
2. Gubkina M.F., Khokhlova Yu.Yu., Petrakova I.Yu., Yukhimenko N.V. Tolerability of individual chemotherapy regimens in children suffering from respiratory tuberculosis and exposed to multiple and extensive drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 3, pp. 29-33. (In Russ.)
3. Klimov G.V., Ershova N.G., Bogdanova E.V. Adverse reactions during treatment of children ill with tuberculosis. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2018, no. 4, pp. 42-47. (In Russ.)
4. Rodina O.V., Borisov S.E., Ivanova D.A. Adverse reactions to various regimens of chemotherapy in respiratory tuberculosis patients. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2020, no. 2, pp. 44-54. (In Russ.)
5. Abdusalomova M., Denisiuk O., Davtyan H., Gadoev J., Abdusamatova B., Parpieva N., Sodikov A. Adverse drug reactions among children with tuberculosis in Tashkent, Uzbekistan, 2019. Int. J. Envir. Res. Publ. Health, 2021, no. 14, pp. 7574.
6. Eribo O.A., du Plessis N., Ozturk M. et al. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell. Mol. Life Sci., 2020, no. 77, pp. 1497-1509.
7. Laghari M., Talpur B.A., Syed Sulaiman S.A., Khan A.H., Bhatti Z. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis. Int. J. Mycobacteriol., 2020, no. 9, pp. 281-288.
Review
For citations:
Bryukhacheva E.O., Kholodov A.A., Ivanov V.I., Kazul G.A., Pyanzova T.V. Risk Factors of Dyspepsia Development during Anti-tuberculosis Chemotherapy in Children. Tuberculosis and Lung Diseases. 2022;100(9):6-10. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-9-6-10
Views:
463
Email this article 